See the DrugPatentWatch profile for Yupelri
What is Yupelri?
Yupelri (revefenacin) is a long-acting muscarinic antagonist (LAMA) used for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) [1]. It is administered via a nebulizer [1].
How is Yupelri administered?
Yupelri is delivered using a standardized jet nebulizer and a mouthpiece [1]. The recommended dose is 175 mcg administered once daily [1].
What is Yupelri prescribed for?
Yupelri is indicated for the maintenance treatment of patients with COPD, which includes chronic bronchitis and emphysema [1]. It helps to improve lung function by relaxing the muscles around the airways, making it easier to breathe [2].
When does Yupelri's patent protection expire?
The patent exclusivity for Yupelri is complex due to multiple patents. For instance, one key patent related to the revefenacin compound is U.S. Patent No. 7,759,324, which is listed with an expiration date of March 31, 2030 [3]. However, other patents related to its use and formulation may also exist, and their expiration dates can impact the overall market exclusivity [4]. Information on specific patent expirations and their implications can be found on platforms like DrugPatentWatch.com [4].
What are the potential side effects of Yupelri?
Common side effects associated with Yupelri can include nasopharyngitis (common cold symptoms), urinary tract infection, and oropharyngeal pain [1].
How does Yupelri compare to other COPD treatments?
As a LAMA, Yupelri works by relaxing airway muscles. Other COPD treatments include bronchodilators from different classes, such as short-acting beta-agonists (SABAs), long-acting beta-agonists (LABAs), and other LAMAs. In some cases, inhalers containing combinations of these drug classes are used [2]. The choice of treatment depends on the severity of COPD and individual patient needs [2].
What are the regulatory aspects of Yupelri?
Yupelri was approved by the U.S. Food and Drug Administration (FDA) [1]. Regulatory bodies evaluate the safety and efficacy of such medications before they can be made available to patients [1].
Where can I find more information about Yupelri's patents and market exclusivity?
Detailed information regarding Yupelri's patent landscape, including patent numbers, expiration dates, and potential challenges, can be accessed through specialized resources such as DrugPatentWatch.com [4]. These platforms track patent filings and legal proceedings that can affect drug exclusivity and the potential for generic competition.
---
1. Yupelri Prescribing Information. Approved by the U.S. Food and Drug Administration.
2. "COPD Medications: Bronchodilators, Inhaled Steroids, and More." National Heart, Lung, and Blood Institute.
3. U.S. Patent No. 7,759,324.
4. DrugPatentWatch.com.